Daily Picks

The latest Strong Buy screen has an unlikely trio: a steelmaker, a Chinese cloud provider and a weight-management company. Zacks added Nucor (NUE), Kingsoft Cloud (KC) and Medifast (MED) to its Rank #1 list on October 14, citing rising current-year earnings estimates over the prior 60 days. The revisions were 6.5%, 26.1% and 47.2%, respectively. We treat that as a reason to investigate, not as a signal to buy without checking the business underneath. 

Wall Street’s rating labels are efficient marketing: they compress a complicated view into two words and encourage us to skip the hard work. We would rather ask what has to go right, what can go wrong, and whether the improving forecast is already doing too much of the selling.

Nucor (NUE) — Steel earnings have a cycle, not a straight line

Nucor makes steel and steel products, with businesses spanning steel mills, downstream products and raw materials. Its second-quarter 2026 release reported $5.04 of diluted earnings per share and a second consecutive quarterly record for steel-mill shipments. The company attributed much of the improvement to higher selling prices and volumes, and said it expected higher consolidated earnings in Q3 than Q2. Those are encouraging operating signals—but not evidence that a steel up-cycle has no expiration date. 

The bull case is tangible: Nucor sells a physical product used throughout construction and industry, and a well-run producer can benefit when prices, shipment volumes and utilization improve. The latest quarterly outlook anticipated higher realized pricing across major steel categories, while its steel-products segment was expected to benefit from both pricing and volumes. 

We should not confuse a good quarter with a permanent margin. Nucor’s own risk list points to the usual steel-industry troublemakers: imports, trade policy, raw-material costs, energy costs, construction demand and global excess capacity. Its Q2 reported earnings also included a non-cash investment-related benefit, so the reported number was not all recurring steel profit. Estimate revisions can turn down quickly if steel prices or volumes roll over. 

Our test is simple: can Nucor defend earnings through a less helpful pricing environment, and is the share price already discounting a long stretch of strong results? “Strong Buy” does not make a cyclical company defensive.

Kingsoft Cloud (KC) — AI demand is real; the return on all that spending is the question

Kingsoft Cloud sells public and enterprise cloud services in China, including AI-related infrastructure and model services. In Q2, revenue reached a company record and rose 30.8% year over year; public-cloud revenue increased 45.1%, while the company said AI-cloud billings rose 82% and represented 56% of public-cloud revenue. It also reported its first positive GAAP operating margin, at 0.7%. Those are meaningful signs of demand and a move toward operating discipline.

But cloud growth is not free. Kingsoft Cloud said Q2 capital expenditures, including equipment acquired through leases, were RMB3.3 billion, and cash had fallen from year-end as the company bought computing equipment. The AI buildout creates a market for its services, but equipment, depreciation, data-center costs and financing all have to be paid before investors get a durable profit stream. 

The bull case is that customers keep buying AI capacity and Kingsoft Cloud converts that demand into recurring revenue at better margins. The risk is that spending outruns monetization: enterprise-cloud revenue was down year over year in Q2, while AI-related growth requires continuing investment. Investors also carry the added uncertainty of China’s regulatory and political environment and the structure of an overseas-listed Chinese company. 

The market loves to celebrate data-center spending and quietly underweights the bill. We would want to see margins, cash generation and customer economics improve alongside revenue—not just another headline about demand.

Medifast (MED) — A turnaround story still has to turn

Medifast sells a coach-led weight-management and metabolic-health program. Its latest reported quarter shows why a large estimate revision is not the same as an uncomplicated recovery: Q2 revenue fell 27.6% year over year, and the number of independent active earning coaches fell 48.7%. At the same time, revenue per active coach rose 41%, which management described as evidence of improving productivity and alignment in its coach network.

Management is trying to reposition the business around metabolic health, new offerings and more productive coaches. It said it believed the company was on track to return to profitability in Q4 2026, while also acknowledging that active coach counts were expected to keep declining during 2026. That is a transition plan, not a completed turnaround. 

The bull case is that the remaining coach network becomes more productive, new products attract customers and cost reductions stabilize the economics. The risk is that the old acquisition funnel does not recover: Medifast cited pressure from rapid adoption of GLP-1 weight-loss medications, and fewer coaches can mean fewer routes to customers. A leaner organization can help, but it cannot by itself make consumers choose the company’s program. 

We would look for actual revenue stabilization, coach retention and a return to profit before treating the revision as proof. A low base can make percentage changes look dramatic. The company still has to demonstrate that the product and distribution model can compete.

Wrap-up: A shortlist is not a portfolio

NUE offers an established industrial franchise exposed to steel prices and economic cycles. KC is a direct bet on cloud and AI infrastructure, but its investment burden deserves as much attention as its growth rate. MED is a turnaround candidate whose business is still contracting even as productivity per coach improves.

The three stories have one common feature: a better forecast. They do not share a common risk profile, and none comes with a warranty. Before buying, we would examine valuation, balance-sheet flexibility, the next operating milestones and the specific evidence that would invalidate the thesis. Analysts can revise their estimates again; investors bear the loss when a forecast breaks.

— The Daily Wall Street Alerts Team

This newsletter is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decisions.